SCHEMBL2816476

SCHEMBL2816476

O=C(O)OC1COC2C(O)COC12

nearest known ligand 0.53

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.53
BCHE P06276 13/20 0.52
THRB P10828 1/20 0.52
LMNA P02545 1/20 0.52
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2890392 1.00 MAPT (0.53) MAPTBCHETHRBLMNAALDH1A1
SCHEMBL11357547 1.00 MAPT (0.53) MAPTBCHETHRBLMNAALDH1A1
SCHEMBL2890384 1.00 MAPT (0.53) MAPTBCHETHRBLMNAALDH1A1
SCHEMBL2816475 1.00 MAPT (0.53) MAPTBCHETHRBLMNAALDH1A1
SCHEMBL24931231 0.89 BCHE (0.48) MAPTBCHEALDH1A1
SCHEMBL16835534 0.89 BCHE (0.48) MAPTBCHEALDH1A1
SCHEMBL16835535 0.89 BCHE (0.48) MAPTBCHEALDH1A1
SCHEMBL15890444 0.86 MAPT (0.55) MAPTBCHETHRBLMNAALDH1A1
SCHEMBL2816474 0.86 MAPT (0.55) MAPTBCHETHRBLMNAALDH1A1
SCHEMBL20564106 0.85 BCHE (0.50) MAPTBCHETHRBLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3220905-B1 COMBINATIONS OF PROSTAGLANDINS AND NITRIC OXIDE DONORS NICOX SA (FR) 2019-10-09 EP claimed
US-20170354634-A1 COMBINATIONS OF PROSTAGLANDINS AND NITRIC OXIDE DONORS NICOX S.A. (FR) 2017-12-14 US claimed
EP-3220905-A1 COMBINATIONS OF PROSTAGLANDINS AND NITRIC OXIDE DONORS Nicox S.A. (FR) 2017-09-27 EP claimed
WO-2016079142-A1 COMBINATIONS OF PROSTAGLANDINS AND NITRIC OXIDE DONORS NICOX S.A. (FR) 2016-05-26 WO claimed
US-10610509-B2 Combinations of prostaglandins and nitric oxide donors NICOX S.A. (FR) 2020-04-07 US disclosed
EP-3220905-B1 COMBINATIONS OF PROSTAGLANDINS AND NITRIC OXIDE DONORS NICOX SA (FR) 2019-10-09 EP disclosed
US-20170354634-A1 COMBINATIONS OF PROSTAGLANDINS AND NITRIC OXIDE DONORS NICOX S.A. (FR) 2017-12-14 US disclosed
EP-3220905-A1 COMBINATIONS OF PROSTAGLANDINS AND NITRIC OXIDE DONORS Nicox S.A. (FR) 2017-09-27 EP disclosed
WO-2016079142-A1 COMBINATIONS OF PROSTAGLANDINS AND NITRIC OXIDE DONORS NICOX S.A. (FR) 2016-05-26 WO disclosed
EP-2238143-B1 NITRIC OXIDE DONOR COMPOUNDS NICOX SA (FR) 2012-08-15 EP disclosed
US-20100249189-A1 NITRIC OXIDE DONOR COMPOUNDS NICOX S.A. (FR) 2010-09-30 US disclosed
US-7645852-B2 Aliphatic polyester copolymer MITSUI CHEMICALS, INC. (JP) 2010-01-12 US disclosed
WO-2009150007-A1 ANGIOTENSIN II RECEPTOR ANTAGONISTS NICOX S.A. (FR) 2009-12-17 WO disclosed
US-20080015331-A1 Aliphatic Polyester Copolymer MITSUI CHEMICALS, INC. (JP) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170354634-A1 COMBINATIONS OF PROSTAGLANDINS AND NITRIC OXIDE DONORS PTGIS, PTGIR, PTGS1 MAPT 4432/4885BCHE 1820/4885THRB 3197/4885
US-20100249189-A1 NITRIC OXIDE DONOR COMPOUNDS NOS3, NOS1, NOS2 MAPT 4444/4885BCHE 951/4885THRB 2627/4885
US-10610509-B2 Combinations of prostaglandins and nitric oxide donors PTGIS, PTGIR, PTGS1 MAPT 4432/4885BCHE 1820/4885THRB 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.